Gynaeguru
Non-Invasive Diagnosisof Endometriosis
An interactive guide for Educational Purpose Only
The Diagnostic Landscape
Endometriosis affects ~10% of women of reproductive age. Historically diagnosed surgically, modern non-invasive methods now offer reliable detection.
10%
Women of reproductive age affected worldwide
7β10
Average years from symptom onset to diagnosis
90%
MRI sensitivity for deep infiltrating endometriosis
3
Core non-invasive diagnostic approaches available today
Clinical Evaluation
Skilled clinicians assess symptom clustersβdysmenorrhea, pelvic pain, dyspareuniaβusing validated questionnaires and physical examination to establish pre-test probability.
First LineNo Cost
Imaging Modalities
Transvaginal ultrasound (TVS) and pelvic MRI provide direct visualisation of endometriomas, deep infiltrating disease, and organ involvement without laparoscopy.
TVSMRI Pelvis80β90% sensitivity
Biomarkers (Emerging)
Blood-based markers (CA-125, cytokines, microRNAs) and novel menstrual blood genomics are under active investigation as minimally-invasive confirmatory tests.
CA-125MicroRNAEmerging
AI-Assisted Diagnosis
Machine learning models trained on ultrasound images, MRI data, and symptom patterns are advancing toward real-time, non-surgical endometriosis detection.
Deep LearningClinical AIResearch Phase
Diagnostic Pathway
A stepwise, non-invasive approach guides clinical decision-making before considering laparoscopy.
Step 01 β Clinical
Symptom Assessment & History
Comprehensive history focusing on cyclic pain, dysmenorrhea severity, infertility, and bowel/bladder symptoms. Use validated questionnaires (e.g., WERF EPHect, BiberogluβBehrman scale) to quantify burden.
Step 02 β Imaging
Transvaginal Ultrasound (TVS)
First-line imaging. Look for ovarian endometrioma (ground-glass echogenicity), “sliding sign” loss (adhesions), and deep infiltrating nodules at rectovaginal septum.
Step 03 β Advanced Imaging
MRI Pelvis (if indicated)
Reserved for deep infiltrating disease, bowel/bladder involvement, pre-surgical mapping, or equivocal ultrasound. Sensitivity 80β90% for deep disease.
Step 04 β Biomarkers
Laboratory & Molecular Tests
CA-125, cytokine panels, or emerging genomic tests may add specificity. Currently adjunctive; not sufficient alone for diagnosis.
Step 05 β Surgical (Last Resort)
Diagnostic Laparoscopy
Still the gold standard for peritoneal disease confirmation. Reserved for failed non-invasive workup, therapeutic intent, or fertility surgery. Increasingly less necessary.
Symptom Checker
Complete the clinical context fields first, then select all presenting symptoms. Cross-field validation will flag clinically inconsistent combinations. This tool provides an indicative suspicion scoreβnot a diagnosis.
π©Ί Clinical Context (required for validation)
Select the patient’s current menstrual status and hormonal therapy. These are cross-validated against selected symptoms to flag clinically inconsistent inputs.
β οΈ Clinically Inconsistent Inputs Detected
Please review the flagged combinations before proceeding. Contradicting fields may produce unreliable suspicion scores.
0%
SUSPICION
Key Symptom Profiles
Dysmenorrhea
Cyclical pelvic pain beginning before or at menstruation onset. Endometriosis-associated dysmenorrhea is often disproportionately severe, progressive, and poorly responsive to OTC NSAIDs.
Specificity for Endometriosis~55%
Chronic Pelvic Pain
Non-cyclic pain persisting β₯6 months. Found in ~70β90% of women with confirmed endometriosis. May involve referred leg/back pain due to infiltrating lesions.
Prevalence in Endometriosis~80%
Dyspareunia
Deep dyspareunia (pain on deep penetration) strongly suggests rectovaginal or uterosacral involvement. Superficial dyspareunia may indicate vulvodynia overlap.
Predictive Value~65%
Infertility
Endometriosis found in 20β50% of infertile women. Mechanisms include tubal distortion, peritoneal fluid toxicity, impaired implantation, and immune dysregulation.
Prevalence in Infertile Women~35%
Imaging Modalities
Non-invasive imaging is the cornerstone of modern endometriosis workup. The choice of modality depends on clinical suspicion, disease extent, and pre-surgical need.
First Line
Transvaginal Ultrasound
AbbreviationTVS / TVUS
Sensitivity (endometrioma)~90%
Deep DIE detectionModerate
CostLow
RadiationNone
Key findingGround-glass cyst
Widely AvailableReal-TimeDynamic Assessment
Advanced Imaging
MRI Pelvis
AbbreviationMRI
Sensitivity (deep DIE)80β90%
Bowel involvementExcellent
CostHigh
RadiationNone
Key usePre-surgical mapping
Soft-tissue detailMulti-compartmentBladder/Bowel
Specialised
Rectal Water-Contrast US
AbbreviationRWC-TVS
Bowel DIE sensitivity~87%
AvailabilitySpecialist centres
CostModerate
RadiationNone
Best forRectal involvement
Bowel mappingPre-op planning
Emerging
Elastography / CEUS
Modality typeUS-enhanced
Evidence levelPreliminary
Fibrosis detectionGood
CostVariable
StatusResearch phase
ResearchAdjunctive
TVS β Detailed Findings & Technique
βΎ
Transvaginal ultrasound is the recommended first-line imaging for suspected endometriosis per ESHRE guidelines. A structured systematic scanning protocol improves diagnostic yield significantly.
Systematic Scanning Protocol (IDEA Consensus):
- Step 1: Assess uterus β retroversion, mobility, adenomyosis features
- Step 2: Ovaries β look for endometrioma (ground-glass echogenicity, no papillary projections)
- Step 3: Sliding sign β gentle probe pressure assesses posterior compartment mobility
- Step 4: Deep nodules β rectovaginal septum, posterior fornix, uterosacral ligaments
- Step 5: Anterior compartment β bladder serosa, pouch of Douglas
ADVANTAGES
- β Widely available, affordable
- β No ionising radiation
- β Real-time dynamic assessment
- β Operator-patient interaction
LIMITATIONS
- β Poor for superficial peritoneal disease
- β Operator dependent
- β Limited field of view for bowel
- β Discomfort for some patients
MRI Pelvis β Protocols & Clinical Indications
βΎ
MRI provides superior soft-tissue contrast resolution and is particularly valuable for mapping complex pelvic disease before major surgery.
Optimal MRI Protocol:
- 3T field strength preferred over 1.5T
- T2-weighted sequences (axial, sagittal, coronal)
- Fat-suppressed T1 to detect haemorrhage (endometrioma)
- Rectal gel and vaginal contrast improve rectovaginal visualisation
- DWI (diffusion-weighted imaging) adds specificity for nodules
Key Detectable Lesions:
π΅ Ovarian endometrioma
π΅ Rectovaginal nodule
π΅ Uterosacral ligament
π΅ Bladder endometriosis
π΅ Sigmoid / rectal DIE
π΅ Ureteral involvement
Biomarker-Based Diagnosis
The search for a reliable blood or urine test for endometriosis is one of the most active areas in gynaecological research. Current evidence and emerging technologies are outlined below.
CA-125 β The Most Studied Marker
Cancer Antigen 125 | Serum glycoprotein
CA-125 is the most widely used blood biomarker for endometriosis surveillance. Elevated in moderate-to-severe disease but lacks sensitivity and specificity for early stages. Normal CA-125 does not exclude endometriosis.
~50%
Sensitivity (overall)
~85%
Specificity
35 U/mL
Standard cut-off
Stage IIIβIV
Best performance
Non-Invasive Treatment
Medical management is the first-line approach for most patients with endometriosis. Hormonal and non-hormonal strategies target pain, disease activity, and quality of life.
Combined Oral Contraceptive Pills (COCP)
βΎ
COCPs are the most widely prescribed first-line hormonal therapy. Continuous use (without pill-free intervals) suppresses menstruation and reduces ectopic implant stimulation.
Benefits
- β Effective dysmenorrhea relief
- β Reduces disease progression
- β Inexpensive, widely available
- β Dual contraceptive benefit
Limitations
- β Not for women seeking pregnancy
- β VTE risk in susceptible patients
- β Breakthrough bleeding common
Estrogen + ProgestogenContinuous use preferredFirst-line
Progestins β Dienogest, MPA, Norethisterone
βΎ
Progestins are highly effective for pain control and disease suppression. They act directly on endometriotic lesions causing decidualisation and eventual atrophy.
Common Agents:
Dienogest 2mg
Most evidence; approved for endometriosis
Medroxyprogesterone 150mg IM
Depot form; 3-monthly injection
Norethisterone 5mg
Oral; widely available, low cost
LNG-IUS (Mirena)
Local progestin; 5-year duration
GnRH Analogues β Leuprolide, Goserelin
βΎ
GnRH agonist analogues cause medical castration via pituitary downregulation, creating a hypo-estrogenic state equivalent to temporary menopause. Highly effective for severe pain.
β οΈ IMPORTANT: Add-Back Therapy Required
Low-dose estrogen-progestogen add-back (e.g., norethisterone 5mg + estradiol 2mg) must be co-prescribed to prevent bone mineral density loss and reduce menopausal symptoms while maintaining therapeutic effect.
Leuprolide
3.75mg IM monthly or 11.25mg every 3 months
Goserelin
3.6mg SC monthly or 10.8mg every 3 months
Maximum duration: typically 6 months without add-back; extended use requires add-back therapy and DEXA monitoring.
GnRH Antagonists β Elagolix, Relugolix
βΎ
GnRH antagonists offer dose-titratable estrogen suppression without the initial flare seen with agonists. Oral administration is a significant advantage over injectable GnRH agonists.
Elagolix (Orilissa)
- β’ 150mg daily (partial suppression)
- β’ 200mg BD (full suppression)
- β’ FDA approved for endometriosis
Relugolix combo
- β’ Fixed combination with E2/NETA
- β’ Once daily oral tablet
- β’ Under regulatory review for endo
Oral once-dailyRapid onsetTitratable suppressionNo initial flare
NSAIDs & Non-Hormonal Pain Management
βΎ
NSAIDs remain first-line symptomatic therapy, particularly for dysmenorrhea. They inhibit cyclooxygenase enzymes, reducing prostaglandin-mediated uterine cramping and inflammation.
π΄
Ibuprofen
400β600mg TDS with food
π
Naproxen
500mg BD; longer half-life
π‘
Mefenamic Acid
500mg TDS; anti-prostaglandin
π΅
Celecoxib
COX-2 selective; GI-sparing
Tip: Pre-emptive NSAID use (starting 1β2 days before expected menstruation) is more effective than reactive dosing. Combine with proton pump inhibitor for GI protection in long-term users.
Lifestyle, Diet & Complementary Therapies
βΎ
π₯ Anti-Inflammatory Diet
- β Omega-3 (oily fish, flaxseed)
- β Fruits & vegetables
- β Whole grains, legumes
- β Red & processed meat
- β Trans fats, refined sugar
- β Alcohol, caffeine
π Physiotherapy
- Pelvic floor rehab
- Manual therapy
- Myofascial release
- Breathing techniques
- Posture correction
π§ Mind-Body
- Yoga (evidence grade B)
- Acupuncture
- CBT for pain
- Mindfulness-based stress reduction
- Heat therapy
AI-Assisted Diagnosis & Future Therapies
Machine learning is poised to transform endometriosis diagnosis. Meanwhile, novel therapeutic targets are advancing through clinical trials.
Interactive AI Assistant β Ask About Endometriosis
π¬
EndoGuide AI
Powered by Clinical AI Β· For Education Only
β οΈ Educational only. Not a substitute for clinical judgment or professional medical advice.
Machine Learning on Ultrasound
Convolutional neural networks trained on TVS images can detect endometriomas and deep infiltrating lesions with sensitivity approaching expert-level performance (~88β92% in validation studies).
CNN modelsImage recognition
Symptom Pattern Recognition
NLP algorithms applied to electronic health records identify high-suspicion symptom clusters years before formal diagnosis, potentially closing the diagnostic delay gap.
NLPEHR mining
Multimodal AI Fusion
Next-generation systems combine imaging, biomarker profiles, and clinical symptoms into unified diagnostic scoresβaiming for >95% accuracy without laparoscopy.
MultimodalResearch phase
Future Non-Invasive Treatments
𧬠Immunotherapy β IL-33 / IL-1Ξ² pathway targeting
π©Έ Anti-angiogenic agents β Bevacizumab analogs
π¬ MicroRNA therapeutics β miR-200 family
βοΈ Selective PR modulators β SPRM research
𧫠Stem cell therapy β endometrial regeneration
π mTOR pathway inhibitors
πΏ Resveratrol β antioxidant clinical trials
π΅ CXCR4 antagonists β lesion homing disruption
π£ Epigenetic modifiers β HDAC inhibitors
π€ CAR-T cell therapy β experimental
When Surgery Remains Necessary
Despite advances in non-invasive approaches, laparoscopic surgery is still indicated in selected cases. Minimally invasive laparoscopic excision (not ablation) is the gold standard surgical approach.
Severe infertilityLarge endometriomas (>4cm)Bowel obstructionUreteral obstructionFailed medical therapyDiagnostic uncertainty